Phoenix Bio

研究発表

研究発表

Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials

    Gane, E. Lim, Y. S. Kim, J. B. Jadhav, V. Shen, L. Bakardjiev, A. I. Huang, S. A. Cathcart, A. L. Lempp, F. A. Janas, M. M. Cloutier, D. J. Kaittanis, C. Sepp-Lorenzino, L, Hinkle, G. Taubel, J. Haslett, P. Milstein, S. Anglero-Rodriguez, Y. I. Hebner, C. M. Pang, P. S. Yuen, M. F.
    J Hepatol. 2023 Jun 6:S0168-8278(23)00352-5. doi: 10.1016/j.jhep.2023.05.023.

    Super-Resolution Microscopy Analysis of Hepatitis B Viral cccDNA and Host Factors

      Doan, P. T. B. Nio, K. Shimakami, T. Kuroki, K. Li, Y. Y. Sugimoto, S. Takayama, H. Okada, H. Kaneko, S. Honda, M. Yamashita, T.
      Viruses. 2023 May 16;15(5):1178. doi: 10.3390/v15051178.

      Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response

        Chida, T. Ishida, Y. Morioka, S. Sugahara, G. Han, C. Lam, B. Yamasaki, C. Sugahara, R. Li, M. Tanaka, Y. Liang, T. J. Tateno, C. Saito, T.
        JCI Insight. 2023 May 8;8(9):e162404. doi: 10.1172/jci.insight.162404.

        Amentoflavone inhibits hepatitis B virus infection via the suppression of preS1 binding to host cells

          Aoki-Utsubo, C. Indrasetiawan, P. Fukano, K. Muramatsu, M. Artanti, N. Hanafi, M. Hotta, H. Kameoka, M.
          Microbiol Immunol. 2023 Mar 16. doi: 10.1111/1348-0421.13064.

          Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection

            Burdette, D. Hyrina, A. Song, Z. Beran, R. K. Cheung, T. Gilmore, S. Kobayashi, T. Li, L. Liu, Y. Niedziela-Majka, A. Medley, J. Mehra, U. Morganelli, P. Novikov, N. Niu, C. Tam, D. Tang, J. Wang, J. Yue, Q. Fletcher, S. P. Holdorf, M. M. Delaney, W. E. th Feierbach, B. Lazerwith, S.
            Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0134822. doi: 10.1128/aac.01348-22.

            Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action

              Toyama, M. Watashi, K. Ikeda, M. Yamashita, A. Okamoto, M. Moriishi, K. Muramatsu, M. Wakita, T. Sharon, A. Baba, M.
              Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0207321. doi: 10.1128/aac.02073-21. Epub 2022 May 23.

              Hepatitis B virus X protein counteracts high mobility group box 1 protein-mediated epigenetic silencing of covalently closed circular DNA

                Kim, E. S. Zhou, J. Zhang, H. Marchetti, A. van de Klundert, M. Cai, D.Yu, X. Mitra, B. Liu, Y. Wang, M. Protzer, U. Guo, H.
                PLoS Pathog. 2022 Jun 9;18(6):e1010576. doi: 10.1371/journal.ppat.1010576.

                Autophagic membranes participate in hepatitis B virus nucleocapsid assembly, precore and core protein trafficking, and viral release

                  Chu, J. Y. K. Chuang, Y. C. Tsai, K. N. Pantuso, J. Ishida, Y. Saito, T. Ou, J. J.

                  Proc Natl Acad Sci U S A. 2022 Jul 26;119(30):e2201927119. doi: 10.1073/pnas.2201927119. Epub 2022 Jul 18.

                  Guanine nucleotide exchange factor DOCK11-binding peptide fused with a single chain antibody inhibits hepatitis B virus infection and replication

                    Ide, M. Tabata, N. Yonemura, Y. Shirasaki, T. Murai, K. Wang, Y. Ishida, A. Okada, H. Honda, M. Kaneko, S. Doi, N. Ito, S. Yanagawa, H.
                    J Biol Chem. 2022 Jul;298(7):102097. doi: 10.1016/j.jbc.2022.102097. Epub 2022 Jun 2.

                    Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection

                      Takemori, T. Sugimoto-Ishige, A. Nishitsuji, H. Futamura, Y. Harada, M. Kimura-Someya, T. Matsumoto, T. Honma, T. Tanaka, M. Yaguchi, M. Isono, K. Koseki, H. Osada, H. Miki, D. Saito, T. Tanaka, T. Fukami, T. Goto, T. Shirouzu, M. Shimotohno, K. Chayama, K.
                      J Virol. 2022 Mar 9;96(5):e0168621. doi: 10.1128/JVI.01686-21. Epub 2022 Jan 5.

                      Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus

                        Ma, Y. Nakamoto, S. Ao, J. Qiang, N. Kogure, T. Ogawa, K. Nakagawa, M. Fujiwara, K. Iwanaga, T. Kojima, R. Kanzaki, H. Koroki, K. Kobayashi, K. Kanogawa, N. Kiyono, S. Nakamura, M. Kondo, T. Nakagawa, R. Ogasawara, S. Muroyama, R. Chiba, T. Kato, J. Kato, N.
                        Int J Mol Sci. 2022 Oct 10;23(19):12015. doi: 10.3390/ijms231912015.

                        N6-methyladenosine Modification of Hepatitis B Virus RNA in the Coding Region of HBx

                          Murata, T. Iwahori, S. Okuno, Y. Nishitsuji, H. Yanagi, Y. Watashi, K. Wakita, T. Kimura, H. Shimotohno, K.
                          Int J Mol Sci. 2023 Jan 23;24(3):2265. doi: 10.3390/ijms24032265.

                          A Novel Anti-HBV Agent, E-CFCP, restores Hepatitis B virus (HBV)-induced Senescence-associated Cellular Markers Perturbation in Human Hepatocytes

                            Takamatsu, Y. Hayashi, S. Kumamoto, H. Imoto, S. Tanaka, Y. Mitsuya, H. Higashi-Kuwata, N.
                            Virus Res. 2023 Mar 23;329:199094. doi: 10.1016/j.virusres.2023.199094.

                            HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

                              Uchida, T. Imamura, M. Hayes, C. N. Suehiro, Y. Teraoka, Y. Ohya, K. Aikata, H. Abe-Chayama, H. Ishida, Y. Tateno, C. Hara, Y. Hino, K. Okamoto, T. Matsuura, Y. Aizaki, H. Wake, K. Kohara, M. Liang, T. J. Oka, S. Chayama, K.
                              Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000335.

                              Discovery of a first-in-class orally available HBV cccDNA inhibitor

                                Wang, L. Zhu, Q. Zhang, J. D. Zhang, Y. Ni, X. Xiang, K. Jiang, J. Li, B. Yu, Y. Hu, H. Zhang, M. Wu, W. Zeng, J. Yan, Z. Dai, J. Sun, K. Zhang, X. Chen, D. Feng, S. Sach Peltason, L. Young, J. A. T. Gao, L.
                                J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. doi: 10.1016/j.jhep.2022.12.014.

                                Pegylated interferon therapy-related microRNA-6126 downregulates sodium taurocholate cotransporting polypeptide expression in hepatocytes

                                  Fujita, K. Nishitsuji, H. Iwama, H. Tadokoro, T. Morishita, A. Mimura, S. Ono, M. Himoto, T. Shimotohno, K. Masaki, T.
                                  Gene. 2022 Nov 24;853:147068. doi: 10.1016/j.gene.2022.147068.

                                  Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

                                    Gilmore, S. A. Tam, D. Cheung, T. L. Snyder, C. Farand, J. Dick, R.Matles, M. Feng, J. Y.Ramirez, R.Li, L. Yu, H. Xu, Y.Barnes, D. Czerwieniec, G. Brendza, K. M. Appleby, T. C. Birkus, G. Willkom, M. Kobayashi, T. Paoli, E. Labelle, M. Boesen, T.Tay, C. H. Delaney, W. E. thNotte, G. T. Schmitz, U. Feierbach, B.
                                    PLoS One. 2022 Dec 7;17(12):e0271145. doi: 10.1371/journal.pone.0271145. eCollection 2022.

                                    Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2

                                      Nakanishi, A. Okumura, H. Hashita, T. Yamashita, A. Nishimura, Y. Watanabe, C. Kamimura, S. Hayashi, S. Murakami, S. Ito, K. Iwao, T. Ikeda, A. Hirose, T. Sunazuka, T. Tanaka, Y. Matsunaga, T.
                                      Viruses. 2022 Nov 8;14(11):2468. doi: 10.3390/v14112468.

                                      Fungal Secondary Metabolite Exophillic Acid Selectively Inhibits the Entry of Hepatitis B and D Viruses

                                        Kobayashi, C. Watanabe, Y. Oshima, M. Hirose, T. Yamasaki, M. Iwamoto, M. Iwatsuki, M. Asami, Y. Kuramochi, K. Wakae, K. Aizaki, H. Muramatsu, M. Sureau, C. Sunazuka, T. Watashi, K.
                                        Viruses. 2022 Apr 6;14(4). pii: v14040764. doi: 10.339/v14040764.

                                        Hepatitis B virus utilizes a retrograde trafficking route via the trans-Golgi network to avoid lysosomal degradation

                                          Li, Y. Y. Kuroki, K. Shimakami, T. Murai, K. Kawaguchi, K. Shirasaki, T. Nio, K. Sugimoto, S. Nishikawa, T. Okada, H. Orita, N. Takayama, H. Wang, Y. Thi Bich, P. D. Ishida, A. Iwabuchi, S.
                                          Cell Mol Gastroenterol Hepatol. 2022 Oct 19. pii: S2352-345X(22)00219-3. doi: 10.1016/j.jcmgh.2022.10.008.